USA flag logo/image

An Official Website of the United States Government

Small Molecular Inhibitors of Artemis as Radiosensitizer

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70738
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
CA110707
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ATHERSYS, INC.
3201 CARNEGIE AVE CLEVELAND, OH 44115-2634
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Small Molecular Inhibitors of Artemis as Radiosensitizer
Agency: HHS
Contract: 1R43CA110707-01
Award Amount: $99,944.00
 

Abstract:

DESCRIPTION (provided by applicant): Recent advances in our understanding of DNA repair mechanisms have led to the identification of the DNA repair specific nuclease, Artemis. Mutations in this enzyme do not affect viability, but enhance cellular sensitivity to ionizing radiation through the prevention of non-homologous-end-joining (NHEJ)-based DNA repair. Hence, small molecule drugs inhibiting the function of this enzyme are likely to be extremely useful as agents to enhance radiotherapeutic treatment of cancer while sparing normal tissue, thereby not adversely affecting patient quality of life. Importantly, administration of Artemis inhibitory compounds before, during, and after radiotherapy should sensitize tumor cells to radiation damage regardless of mitotic state at the time of treatment, effectively killing slow growing hypoxic tumor cells which are normally resistant to radiotherapy. This phase I application describe studies that will result in the screening of a small molecule library to identify inhibitors of Artemis activity. The subsequent Phase II application will be directed toward development and optimization of lead small molecule candidates that will be tested in-vitro and in-vivo to determine the extent to which these compounds sensitize tumor cells to radiation damage. There are three specific aims for this phase I application: 1) Purify Artemis in sufficient quantities for HTS and optimize screening methods. 2) Screen a approximately 100,000-member small molecule compound library for inhibitors of Artemis. 3) Determine compound specificity toward Artemis and obtain IC50 values for specific compounds.

Principal Investigator:

Stephen E. Rundlett
2164319900
SRUNDLETT@ATHERSYS.COM

Business Contact:

John Harrington
2164319900
jharrington@athersys.com
Small Business Information at Submission:

ATHERSYS, INC.
ATHERSYS, INC. 3201 CARNEGIE AVE CLEVELAND, OH 44115

EIN/Tax ID: 341830213
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No